CR9479A - Moduladores canabinoides de tetrahidrotiopirano pirazol - Google Patents

Moduladores canabinoides de tetrahidrotiopirano pirazol

Info

Publication number
CR9479A
CR9479A CR9479A CR9479A CR9479A CR 9479 A CR9479 A CR 9479A CR 9479 A CR9479 A CR 9479A CR 9479 A CR9479 A CR 9479A CR 9479 A CR9479 A CR 9479A
Authority
CR
Costa Rica
Prior art keywords
tetrahydrotiopirane
pirazol
canabinoid modulators
canabinoid
modulators
Prior art date
Application number
CR9479A
Other languages
English (en)
Spanish (es)
Inventor
Liotta Fina
Lu Huajun
Xia Mingde
P Wachter Michael
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR9479A publication Critical patent/CR9479A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CR9479A 2005-03-31 2007-10-29 Moduladores canabinoides de tetrahidrotiopirano pirazol CR9479A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66689805P 2005-03-31 2005-03-31

Publications (1)

Publication Number Publication Date
CR9479A true CR9479A (es) 2008-09-09

Family

ID=36587178

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9479A CR9479A (es) 2005-03-31 2007-10-29 Moduladores canabinoides de tetrahidrotiopirano pirazol

Country Status (18)

Country Link
US (2) US20060223798A1 (enExample)
EP (1) EP1863479B1 (enExample)
JP (1) JP5127697B2 (enExample)
KR (1) KR20080004559A (enExample)
CN (1) CN101189007A (enExample)
AT (1) ATE416768T1 (enExample)
AU (1) AU2006232945B2 (enExample)
BR (1) BRPI0609790A2 (enExample)
CA (1) CA2603104A1 (enExample)
CO (1) CO6321135A2 (enExample)
CR (1) CR9479A (enExample)
DE (1) DE602006004197D1 (enExample)
EA (1) EA200702130A1 (enExample)
IL (1) IL186430A0 (enExample)
MX (1) MX2007012233A (enExample)
NO (1) NO20075463L (enExample)
WO (1) WO2006107561A1 (enExample)
ZA (1) ZA200709342B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101863903B (zh) * 2010-06-08 2014-03-12 沈阳药科大学 1,4-二氢噻吩并[3’,2’:5,6]噻喃并[4,3-c]吡唑-3-羧酸衍生物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
EP1254115A2 (en) * 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
WO2003035005A2 (en) * 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
NO20075463L (no) 2007-12-21
AU2006232945A1 (en) 2006-10-12
EP1863479A1 (en) 2007-12-12
EA200702130A1 (ru) 2008-04-28
IL186430A0 (en) 2008-01-20
CO6321135A2 (es) 2011-09-20
CN101189007A (zh) 2008-05-28
JP5127697B2 (ja) 2013-01-23
KR20080004559A (ko) 2008-01-09
ZA200709342B (en) 2009-09-30
CA2603104A1 (en) 2006-10-12
US20060223798A1 (en) 2006-10-05
EP1863479B1 (en) 2008-12-10
US7524964B2 (en) 2009-04-28
ATE416768T1 (de) 2008-12-15
BRPI0609790A2 (pt) 2010-04-27
MX2007012233A (es) 2008-03-18
US20080085899A1 (en) 2008-04-10
DE602006004197D1 (de) 2009-01-22
AU2006232945B2 (en) 2012-02-23
JP2008535829A (ja) 2008-09-04
WO2006107561A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
TW200602324A (en) Tetrahydro-indazole cannabinoid modulators cross reference to related applications
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
SG155188A1 (en) Pyrrole derivatives as pharmaceutical agents
ZA200803533B (en) Hexahydro cyclooctyl pyrazole cannabinoid modulators
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
MX2010001714A (es) Moduladores de canabinoides 5-vinilfenil-1-fenil-pirazol sustituidos.
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
BRPI0517378A (pt) moduladores de tetraidro piridinil pirazol canabinóide
NO20082505L (no) Substtuert 5-heteroaryl-1-fenyl-pyrazol-cannabinoid-modulatorer
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
UA98487C2 (en) Hexahydro-cycloheptapyrazole cannabinoid modulators
ZA200803532B (en) Hexahydro-cycloheptapyrazole cannabinoid modulators
CR9479A (es) Moduladores canabinoides de tetrahidrotiopirano pirazol
MX2009010159A (es) Moduladores de cannabinoides hexahidro-ciclooctil pirazol.
ATE502947T1 (de) 4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren
MX2007004040A (es) Uso para alfa-simpatomimeticos con estructura de 2-imidazolina.
UA93689C2 (ru) Фармацевтическая композиция ингибиторов дипептидилпептидазы

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)